ES2902549T3 - Inhibidor de tirosina cinasa y aplicación del mismo - Google Patents
Inhibidor de tirosina cinasa y aplicación del mismo Download PDFInfo
- Publication number
- ES2902549T3 ES2902549T3 ES17850066T ES17850066T ES2902549T3 ES 2902549 T3 ES2902549 T3 ES 2902549T3 ES 17850066 T ES17850066 T ES 17850066T ES 17850066 T ES17850066 T ES 17850066T ES 2902549 T3 ES2902549 T3 ES 2902549T3
- Authority
- ES
- Spain
- Prior art keywords
- compound
- mmol
- distillation
- added
- dried
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610822529.0A CN107235896B (zh) | 2016-09-13 | 2016-09-13 | 酪氨酸激酶抑制剂及其应用 |
| PCT/CN2017/089501 WO2018049861A1 (zh) | 2016-09-13 | 2017-06-22 | 酪氨酸激酶抑制剂及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2902549T3 true ES2902549T3 (es) | 2022-03-28 |
Family
ID=59982910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17850066T Active ES2902549T3 (es) | 2016-09-13 | 2017-06-22 | Inhibidor de tirosina cinasa y aplicación del mismo |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10882853B2 (enExample) |
| EP (1) | EP3511327B1 (enExample) |
| JP (1) | JP7487921B2 (enExample) |
| KR (2) | KR102382039B1 (enExample) |
| CN (2) | CN107235896B (enExample) |
| AU (1) | AU2017325641B2 (enExample) |
| ES (1) | ES2902549T3 (enExample) |
| WO (1) | WO2018049861A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3070013A1 (en) | 2017-07-18 | 2019-01-24 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
| WO2019148043A1 (en) | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| CR20250117A (es) | 2018-01-26 | 2025-05-09 | Exelixis Inc | COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE CINASAS (Divisional 2020-0355) |
| SG11202006921PA (en) * | 2018-01-26 | 2020-08-28 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
| AR119069A1 (es) * | 2019-06-04 | 2021-11-24 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de quinasas |
| CN112358469A (zh) * | 2020-03-18 | 2021-02-12 | 北京康辰药业股份有限公司 | 血管生成抑制剂、其制备方法及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2744997A1 (en) * | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and method of use |
| UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| US8293897B2 (en) * | 2008-10-14 | 2012-10-23 | Ning Xi | Compounds comprising a spiro-ring and methods of use |
| AU2010229147B2 (en) * | 2009-03-21 | 2012-07-05 | Sunshine Lake Pharma Co., Ltd. | Amino ester derivatives, salts thereof and methods of use |
| US8664244B2 (en) * | 2010-09-12 | 2014-03-04 | Advenchen Pharmaceuticals, LLC | Compounds as c-Met kinase inhibitors |
| CN105884695B (zh) * | 2015-02-13 | 2019-02-26 | 山东轩竹医药科技有限公司 | 杂环衍生物类酪氨酸激酶抑制剂 |
| CN104817497B (zh) * | 2015-03-20 | 2017-03-08 | 南京众睿缘生物科技有限公司 | 一种炔代喹啉衍生物及其制备方法和用途 |
| CN105017163A (zh) * | 2015-08-25 | 2015-11-04 | 佛山市赛维斯医药科技有限公司 | 双乙氧基苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及其用途 |
| CN105001168A (zh) * | 2015-08-25 | 2015-10-28 | 佛山市赛维斯医药科技有限公司 | 三烷氧基取代的苯并喹唑啉类酪氨酸激酶抑制剂及其用途 |
| CN105218445B (zh) * | 2015-08-25 | 2018-05-22 | 江苏中邦制药有限公司 | 一种酪氨酸激酶抑制剂Foretinib的制备方法 |
| CN105085416A (zh) * | 2015-08-25 | 2015-11-25 | 佛山市赛维斯医药科技有限公司 | 一类硝基取代的双烷氧苯并喹唑啉类酪氨酸激酶抑制剂及用途 |
-
2016
- 2016-09-13 CN CN201610822529.0A patent/CN107235896B/zh active Active
- 2016-09-13 CN CN201910822704.XA patent/CN110437145A/zh active Pending
-
2017
- 2017-06-22 WO PCT/CN2017/089501 patent/WO2018049861A1/zh not_active Ceased
- 2017-06-22 KR KR1020217037589A patent/KR102382039B1/ko active Active
- 2017-06-22 ES ES17850066T patent/ES2902549T3/es active Active
- 2017-06-22 KR KR1020197010451A patent/KR20190045354A/ko not_active Ceased
- 2017-06-22 EP EP17850066.6A patent/EP3511327B1/en active Active
- 2017-06-22 JP JP2019515307A patent/JP7487921B2/ja active Active
- 2017-06-22 US US16/333,050 patent/US10882853B2/en active Active
- 2017-06-22 AU AU2017325641A patent/AU2017325641B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210143935A (ko) | 2021-11-29 |
| CN107235896B (zh) | 2019-11-05 |
| JP7487921B2 (ja) | 2024-05-21 |
| KR20190045354A (ko) | 2019-05-02 |
| EP3511327A1 (en) | 2019-07-17 |
| KR102382039B1 (ko) | 2022-04-01 |
| EP3511327B1 (en) | 2021-10-27 |
| US10882853B2 (en) | 2021-01-05 |
| WO2018049861A1 (zh) | 2018-03-22 |
| EP3511327A4 (en) | 2019-08-07 |
| CN110437145A (zh) | 2019-11-12 |
| CN107235896A (zh) | 2017-10-10 |
| AU2017325641A1 (en) | 2019-04-11 |
| AU2017325641B2 (en) | 2021-08-26 |
| JP2019529435A (ja) | 2019-10-17 |
| US20190248772A1 (en) | 2019-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2902549T3 (es) | Inhibidor de tirosina cinasa y aplicación del mismo | |
| US10793543B2 (en) | Selective C-KIT kinase inhibitor | |
| CN107922417B (zh) | 蝶啶酮衍生物作为egfr抑制剂的应用 | |
| BR112017003312B1 (pt) | Compostos de indazol como inibidores de fgfr quinase, preparação e uso dos mesmos | |
| KR20180043794A (ko) | 피라졸 피리미딘 유도체 및 이의 용도 | |
| ES2931537T3 (es) | Pirrolopiridinas sustituidas como inhibidores de la quinasa similar al receptor de activina | |
| CN107698603B (zh) | 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用 | |
| KR20150074186A (ko) | 헤테로아릴기 알킨 화합물 및 그 응용 | |
| CN103739616B (zh) | 含噻唑基雷帕霉素类衍生物及其应用 | |
| EP2928466B1 (en) | Use of maleimide derivatives for preventing and treating leukemia | |
| CN112047944A (zh) | 一种选择性抑制激酶化合物及其用途 | |
| AU2016415412A1 (en) | Antimetastatic 2H-selenopheno[3,2-h]chromenes, synthesis thereof, and methods of using same agents | |
| WO2021017795A1 (zh) | 一种α,β-不饱和酮衍生物、制备方法及作为药物的用途 | |
| EA028545B1 (ru) | Бициклическое азотсодержащее ароматическое гетероциклическое амидное соединение | |
| CN102688234B (zh) | 吲哚酮衍生物作为rsk2抑制剂的合成与应用 | |
| CN114315952A (zh) | 丹参酮i衍生物、其制备方法及其应用 | |
| WO2021115495A1 (zh) | 一种小分子含硫杂环化合物 | |
| EP4091670A1 (en) | Crystal of imidazopyridinone compound or salt thereof | |
| WO2015182625A1 (ja) | Ｒａｓ活性阻害薬及びその用途 | |
| CN104045632A (zh) | 抗肿瘤药物苯并二氢吡喃（噻喃）酰胺类化合物及其药学上可接受的盐及制备方法和应用 | |
| CN115244054B (zh) | 次黄嘌呤化合物的晶体 | |
| CN109206435A (zh) | 噻吩并[3,2-d]嘧啶类化合物及其制备方法和医药用途 | |
| KR20240101433A (ko) | Ron 억제제로서 신규한 화합물 | |
| EP4617269A1 (en) | Novel compound as ron inhibitor | |
| WO2024235106A1 (zh) | 稠合吡咯环或稠合吡啶环的化合物 |